Guardian Pharmacy Services, Inc.
GRDNHealthcareNASDAQMedical Care Facilities · Last scanned Sep 9, 2026
Scan Results
Daily timeframeGuardian Pharmacy Services, Inc., a pharmacy service company, provides a suite of technology-enabled services to help residents of long-term health care facilities (LTCFs) in the United States. The $2.69B market capitalization puts GRDN squarely in mid-cap range for its industry. The company's individualized clinical, drug dispensing, and administration capabilities are used to serve the needs of residents in lower acuity LTCFs, such as assisted living facilities, behavioral health facilities, and group homes.
Market Cap
$2.69B
Beta
—
P/E (TTM)
40.82
P/E (Fwd)
29.69
EPS (TTM)
$1.04
EPS (Fwd)
$1.43
ROE
30.4%
ROA
13.5%
Cash
$89.8M
Total Debt
$39.3M
Free CF
$64.5M
52W Change
40.7%
Annual Financials
Cash vs Debt
Where GRDN stands vs its 150-day and 200-day moving averages
As of the September 3, 2026 close, GRDN finished 3.89% above its 150-day moving average ($37.58) and 9.48% above its 200-day moving average ($35.66). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is GRDN overbought or oversold?
At the September 3, 2026 close, GRDN's RSI(14) was 55.6, in neutral territory (between 30 and 70). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
With $89.8M in cash and $39.3M in debt, GRDN maintains more liquidity than leverage. This favorable balance sheet position can be an asset when capital markets become less accommodating. The company generates $64.5M in free cash flow annually, which funds everything from R&D to shareholder returns without needing external financing. Return on equity stands at 30.4%, which is exceptionally high for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. Return on assets of 13.5% further supports the picture of efficient asset utilization. Revenue has grown from $908.9M (2022) to $1.45B (2025), reflecting a 59% increase over the period.
With cash comfortably exceeding debt, GRDN has financial flexibility that may help navigate uncertain periods. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence Guardian Pharmacy Services, Inc.'s trajectory.